Anzeige
Mehr »
Freitag, 05.09.2025 - Börsentäglich über 12.000 News
SuperBuzz x Prymatica: Ein Vertriebsdeal, der KI-Hype in B2B-Umsätze verwandeln könnte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
220 Leser
Artikel bewerten:
(1)

Avania Strengthens Leadership Team with Appointment of Four New Executives

BILTHOVEN, Netherlands and BOSTON, Sept. 04, 2025, the leading global MedTech advisory and clinical development partner, is pleased to announce strategic leadership appointments of four distinguished executives. As the MedTech industry navigates increasing regulatory complexity and technological innovation, these new leaders bring decades of combined experience in clinical research, regulatory affairs, operations, information technology, and business development, further reinforcing Avania's commitment to excellence and growth.

The newly appointed executives are:

  • Angela Johnson (https://www.avaniaclinical.com/leadership-team/angela-johnson/), PhD, RAC,Senior Vice President, Advisory Services - Dr. Johnson has more than 25 years of experience leading regulatory strategy (https://www.avaniaclinical.com/solutions/emerging-technology-and-product-development-strategy/), clinical development, and market access (https://www.avaniaclinical.com/solutions/market-access/) initiatives for medical devices, combination products, and AI/SaMD technologies, ranging from early-stage ventures to multinational companies. As leader of Avania's global advisory practice, she partners with MedTech innovators to navigate FDA, EU (MDR/IVDR), Asia-Pacific (TGA, PMDA, NMPA), and global regulatory frameworks. Her expertise strengthens Avania's ability to deliver high-impact, insight-driven counsel, accelerating time-to-market for breakthrough technologies, and enabling clients to thrive in an increasingly complex, evolving global landscape.
  • Paul Southam (https://www.avaniaclinical.com/leadership-team/paul-southam/), Chief Information Officer (CIO) - Southam joins Avania as Chief Information Officer, bringing over two decades of global leadership experience in information technology and digital transformation. With a proven track record of aligning IT strategy with business objectives, Paul will lead Avania's global technology initiatives - driving innovation, security, and operational efficiency across the organization.
  • Marianne Martin, Vice President, Global Project Management - Martin has over 20 years of global leadership experience in clinical research operations (https://www.avaniaclinical.com/solutions/clinical-operations/) and program delivery, spanning multiple therapeutic areas and including medical devices and combination products. Martin has a strong track record of successfully leading complex, global, multi-center clinical trials, with deep expertise in the fundamentals of project management and customer service. Martin will oversee Avania's global project management teams, ensuring operational excellence and strategic alignment across all client programs.
  • Karen Auten, Vice President, Global Clinical Operations (https://www.avaniaclinical.com/solutions/clinical-operations/) - Auten brings over two decades of leadership in clinical research, global clinical trial management, program delivery, and operational strategy within the medical device and life sciences industries. Auten will lead Avania's global clinical operations, overseeing the execution of clinical trials from first-in-human through post-market studies. Auten is recognized for her ability to lead high-performing teams, streamline operational processes, and deliver impactful results in complex, regulated environments. Auten's appointment underscores Avania's commitment to advancing clinical innovation and operational excellence on a global scale.

"These appointments mark an exciting chapter in Avania's evolution as we scale to meet increasing global demand for MedTech regulatory and clinical expertise," said Jason Monteleone, Chief Executive Officer of Avania. "Each of these leaders brings a unique set of skills and insights that align with our mission to advance MedTech innovation through expert-driven, customized solutions. Their collective expertise will help us better serve our clients, and navigate the dynamic healthcare landscape."

With these appointments, Avania strengthens its position as the premier global partner for MedTech companies worldwide, delivering clinical research and regulatory solutions that accelerate innovation, and drive success from concept to commercialization.

For more information, please visit www.avaniaclinical.com.

About Avania

Avania is the leading global MedTech advisory and clinical development partner with a focus on medical devices, diagnostics/IVDs, and digital health. Core offerings include full service clinical research outsourcing, market access, reimbursement, regulatory, and product development advisory services. Avania's vision is to be your trusted global partner in the evolution of your medical technology from innovation to commercialization to improving patient health and well-being.

Media Contact:
Jason Monteleone
Tel: +1 (978) 760-8043
Email: Jason.Monteleone@avaniaclinical.com


© 2025 GlobeNewswire (Europe)
Solarbranche vor dem Mega-Comeback?
Lange galten Solaraktien als Liebling der Börse, dann kam der herbe Absturz: Zinsschock, Überkapazitäten aus China und ein Preisverfall, der selbst Marktführer wie SMA Solar, Enphase Energy oder SolarEdge massiv unter Druck setzte. Viele Anleger haben der Branche längst den Rücken gekehrt.

Doch genau das könnte jetzt die Chance sein!
Die Kombination aus KI-Explosion und Energiewende bringt die Branche zurück ins Rampenlicht:
  • Rechenzentren verschlingen Megawatt – Solarstrom bietet den günstigsten Preis je Kilowattstunde
  • Moderne Module liefern Wirkungsgrade wie Atomkraftwerke
  • hina bremst Preisdumping & pusht massiv den Ausbau
Gleichzeitig locken viele Solar-Aktien mit historischen Tiefstständen und massiven Short-Quoten, ein perfekter Nährboden für Kursrebound und Squeeze-Rally.

In unserem exklusiven Gratis-Report zeigen wir dir, welche 4 Solar-Aktien besonders vom Comeback profitieren dürften und warum jetzt der perfekte Zeitpunkt für einen Einstieg sein könnte.

Laden Sie jetzt den Spezialreport kostenlos herunter, bevor die Erholung am Markt beginnt!

Dieses Angebot gilt nur für kurze Zeit – also nicht zögern, jetzt sichern!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.